Colorado has capped the price of co-pays for insulin, making it the first state to enact a law that combats the soaring costs for the medication that have doubled in the last seven years.
Democratic Gov. Jared Polis signed the bill into law earlier this week, restricting the price for insured patients to co-pays of US$100 a month, according to the Denver Post. The law goes into effect in January.
The skyrocketing cost of insulin has prompted lawmakers, including Congress, to call for price caps and pharmaceutical companies to find ways to drop the cost for patients.
Between 2012 and 2016, prices for insulin nearly doubled, according to a March report from the US House of Representatives. Insulin can cost between US$600 and US$1,000 a month on average.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
PepsiCo Sued Over Alleged Price Discrimination Involving Walmart
Jan 19, 2025 by
CPI
Regulators Approve Conditions for Multibillion-Dollar Oil Mergers
Jan 19, 2025 by
CPI
FTC Reaches Settlement with Private Equity Firm Over Antitrust Allegations in Texas
Jan 19, 2025 by
CPI
FTC Raises Antitrust Concerns Over Big Tech’s AI Partnerships
Jan 19, 2025 by
CPI
MultiPlan and Insurers Move to Dismiss Antitrust Allegations Amid Growing Legal Challenges
Jan 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand